FusionNeoAntigen Logo

Home

Download

Statistics

Examples

Help

Contact

Terms of Use

Center for Computational Systems Medicine
leaf

Fusion Gene and Fusion Protein Summary

leaf

Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)

leaf

Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)

leaf

Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)

leaf

Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)

leaf

Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)

leaf

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)

leaf

Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)

leaf

Potential target of CAR-T therapy development

leaf

Information on the samples that have these potential fusion neoantigens

leaf

Fusion Protein Targeting Drugs - (Manual Curation)

leaf

Fusion Protein Related diseases - (Manual Curation)

Fusion Protein:TET1-TMEM222

Fusion Gene and Fusion Protein Summary

check button Fusion gene summary
Fusion partner gene informationFusion gene name: TET1-TMEM222
FusionPDB ID: 90163
FusionGDB2.0 ID: 90163
HgeneTgene
Gene symbol

TET1

TMEM222

Gene ID

80312

84065

Gene nametet methylcytosine dioxygenase 1transmembrane protein 222
SynonymsCXXC6|LCX|bA119F7.1C1orf160
Cytomap

10q21.3

1p36.11

Type of geneprotein-codingprotein-coding
Descriptionmethylcytosine dioxygenase TET1CXXC finger 6CXXC zinc finger 6CXXC-type zinc finger protein 6TET1 splice variant VP_DE4TET1 splice variant VP_DE456leukemia-associated protein with a CXXC domainten-eleven translocation 1 gene proteinten-eleven trantransmembrane protein 222
Modification date2020031320200313
UniProtAcc

Q8NFU7

Main function of 5'-partner protein: FUNCTION: Dioxygenase that catalyzes the conversion of the modified genomic base 5-methylcytosine (5mC) into 5-hydroxymethylcytosine (5hmC) and plays a key role in active DNA demethylation (PubMed:19372391, PubMed:21496894). Also mediates subsequent conversion of 5hmC into 5-formylcytosine (5fC), and conversion of 5fC to 5-carboxylcytosine (5caC) (PubMed:21778364). In addition to its role in DNA demethylation, plays a more general role in chromatin regulation by recruiting histone modifying protein complexes to alter histone marks and chromatin accessibility, leading to both activation and repression of gene expression (PubMed:33833093). Plays therefore a role in many biological processes and diseases, including stem cell maintenance, T and B-cell development, inflammation regulation, genomic imprinting, neural activity or DNA repair (PubMed:31278917). Involved in the balance between pluripotency and lineage commitment of cells it plays a role in embryonic stem cells maintenance and inner cell mass cell specification. Plays an important role in the tumorigenicity of glioblastoma cells. TET1-mediated production of 5hmC acts as a recruitment signal for the CHTOP-methylosome complex to selective sites on the chromosome, where it methylates H4R3 and activates the transcription of genes involved in glioblastomagenesis (PubMed:25284789). Binds preferentially to DNA containing cytidine-phosphate-guanosine (CpG) dinucleotides over CpH (H=A, T, and C), hemimethylated-CpG and hemimethylated-hydroxymethyl-CpG (PubMed:29276034). Plays an essential role in the protection and maintenance of transcriptional and developmental programs together with QSER1 to inhibit the binding of DNMT3A/3B and therefore de novo methylation (PubMed:33833093). {ECO:0000269|PubMed:12124344, ECO:0000269|PubMed:19372391, ECO:0000269|PubMed:19372393, ECO:0000269|PubMed:21496894, ECO:0000269|PubMed:21778364, ECO:0000269|PubMed:25284789, ECO:0000269|PubMed:29276034, ECO:0000269|PubMed:31278917, ECO:0000269|PubMed:33833093}.
.
Ensembl transtripts involved in fusion geneENST idsENST00000373644, ENST00000374076, 
ENST00000608611, 
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)* DoF score10 X 14 X 7=9807 X 5 X 6=210
# samples 149
** MAII scorelog2(14/980*10)=-2.8073549220576
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
log2(9/210*10)=-1.22239242133645
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
Fusion gene context

PubMed: TET1 [Title/Abstract] AND TMEM222 [Title/Abstract] AND fusion [Title/Abstract]

Fusion neoantigen context

PubMed: TET1 [Title/Abstract] AND TMEM222 [Title/Abstract] AND neoantigen [Title/Abstract]

Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)TET1(70411693)-TMEM222(27660449), # samples:1
Anticipated loss of major functional domain due to fusion event.TET1-TMEM222 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
TET1-TMEM222 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
TET1-TMEM222 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
TET1-TMEM222 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

check button Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez
PartnerGeneGO IDGO termPubMed ID


check button Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr10:70411693/chr1:27660449)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.
FGviewer

check buttonRetention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

check buttonFusion gene breakpoints across TET1 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure

check buttonFusion gene breakpoints across TMEM222 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure


Top

Fusion Amino Acid Sequences


check buttonFusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandSeq length
(transcript)
BP loci
(transcript)
Predicted start
(transcript)
Predicted stop
(transcript)
Seq length
(amino acids)
ENST00000373644TET1chr1070411693-ENST00000374076TMEM222chr127660449+5826457617648911571
ENST00000373644TET1chr1070411693-ENST00000608611TMEM222chr127660449+5826457617648911571

check buttonDeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandNo-coding scoreCoding score
ENST00000373644ENST00000374076TET1chr1070411693-TMEM222chr127660449+0.0003924570.9996076
ENST00000373644ENST00000608611TET1chr1070411693-TMEM222chr127660449+0.0003924570.9996076

check button Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for TET1-TMEM222

check button +/-13 AA sequence from the breakpoints of the fusion protein sequences.
HgeneHchrHbpTgeneTchrTbpLength(fusion protein)BP in fusion proteinPeptide
TET1chr1070411693TMEM222chr12766044945761466GPSVAAVREIMENRYWKLDPAQVYAS

Top

Potential FusionNeoAntigen Information of TET1-TMEM222 in HLA I

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
TET1-TMEM222_70411693_27660449.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)
Fusion geneHchrHbpTgeneTchrTbpHLA IFusionNeoAntigen peptideBinding scoreImmunogenic scoreNeoantigen start (at BP 13)Neoantigen end (at BP 13)
TET1-TMEM222chr1070411693chr1276604494576HLA-B47:01REIMENRY0.99960.5462715
TET1-TMEM222chr1070411693chr1276604494576HLA-B18:01REIMENRY0.99280.9016715
TET1-TMEM222chr1070411693chr1276604494576HLA-B44:03REIMENRYW0.99890.9345716
TET1-TMEM222chr1070411693chr1276604494576HLA-A30:08AVREIMENR0.99340.8176514
TET1-TMEM222chr1070411693chr1276604494576HLA-B47:01REIMENRYW0.99230.5521716
TET1-TMEM222chr1070411693chr1276604494576HLA-A74:09AVREIMENR0.98850.6736514
TET1-TMEM222chr1070411693chr1276604494576HLA-A74:11AVREIMENR0.98850.6736514
TET1-TMEM222chr1070411693chr1276604494576HLA-A74:03AVREIMENR0.98850.6736514
TET1-TMEM222chr1070411693chr1276604494576HLA-B39:06NRYWKLDPA0.98170.58781221
TET1-TMEM222chr1070411693chr1276604494576HLA-A31:06AVREIMENR0.96690.5244514
TET1-TMEM222chr1070411693chr1276604494576HLA-A31:02AVREIMENR0.8670.6967514
TET1-TMEM222chr1070411693chr1276604494576HLA-B08:01IMENRYWKL0.56160.7383918
TET1-TMEM222chr1070411693chr1276604494576HLA-B15:01AVREIMENRY0.99960.9336515
TET1-TMEM222chr1070411693chr1276604494576HLA-B44:03VREIMENRYW0.82130.937616
TET1-TMEM222chr1070411693chr1276604494576HLA-B57:01AVREIMENRYW0.99990.9776516
TET1-TMEM222chr1070411693chr1276604494576HLA-B44:03AVREIMENRYW0.90830.9594516
TET1-TMEM222chr1070411693chr1276604494576HLA-B73:01NRYWKLDPA0.99690.83271221
TET1-TMEM222chr1070411693chr1276604494576HLA-A31:01AVREIMENR0.99140.6294514
TET1-TMEM222chr1070411693chr1276604494576HLA-B15:07AVREIMENRY0.99920.7799515
TET1-TMEM222chr1070411693chr1276604494576HLA-A31:01AAVREIMENR0.94970.7702414
TET1-TMEM222chr1070411693chr1276604494576HLA-B18:11REIMENRY0.9990.8831715
TET1-TMEM222chr1070411693chr1276604494576HLA-B18:05REIMENRY0.99280.9016715
TET1-TMEM222chr1070411693chr1276604494576HLA-B18:03MENRYWKL0.98610.7471018
TET1-TMEM222chr1070411693chr1276604494576HLA-B44:07REIMENRYW0.99890.9345716
TET1-TMEM222chr1070411693chr1276604494576HLA-B44:13REIMENRYW0.99890.9345716
TET1-TMEM222chr1070411693chr1276604494576HLA-B44:26REIMENRYW0.99890.9345716
TET1-TMEM222chr1070411693chr1276604494576HLA-A74:01AVREIMENR0.98850.6736514
TET1-TMEM222chr1070411693chr1276604494576HLA-B08:18IMENRYWKL0.56160.7383918
TET1-TMEM222chr1070411693chr1276604494576HLA-B08:12IMENRYWKL0.38580.9038918
TET1-TMEM222chr1070411693chr1276604494576HLA-C07:04IMENRYWKL0.32190.9396918
TET1-TMEM222chr1070411693chr1276604494576HLA-B15:34AVREIMENRY0.99960.9336515
TET1-TMEM222chr1070411693chr1276604494576HLA-B15:125AVREIMENRY0.99960.9336515
TET1-TMEM222chr1070411693chr1276604494576HLA-B15:135AVREIMENRY0.99960.9472515
TET1-TMEM222chr1070411693chr1276604494576HLA-B15:33AVREIMENRY0.99960.9336515
TET1-TMEM222chr1070411693chr1276604494576HLA-B15:50AVREIMENRY0.99940.895515
TET1-TMEM222chr1070411693chr1276604494576HLA-B15:35AVREIMENRY0.9990.9375515
TET1-TMEM222chr1070411693chr1276604494576HLA-B15:12AVREIMENRY0.99720.8868515
TET1-TMEM222chr1070411693chr1276604494576HLA-B44:26VREIMENRYW0.82130.937616
TET1-TMEM222chr1070411693chr1276604494576HLA-B44:07VREIMENRYW0.82130.937616
TET1-TMEM222chr1070411693chr1276604494576HLA-B44:13VREIMENRYW0.82130.937616
TET1-TMEM222chr1070411693chr1276604494576HLA-B57:04AVREIMENRYW0.99990.7416516
TET1-TMEM222chr1070411693chr1276604494576HLA-B57:10AVREIMENRYW0.99990.9776516
TET1-TMEM222chr1070411693chr1276604494576HLA-B58:06AVREIMENRYW0.99970.9005516
TET1-TMEM222chr1070411693chr1276604494576HLA-B44:13AVREIMENRYW0.90830.9594516
TET1-TMEM222chr1070411693chr1276604494576HLA-B44:26AVREIMENRYW0.90830.9594516
TET1-TMEM222chr1070411693chr1276604494576HLA-B44:07AVREIMENRYW0.90830.9594516

Top

Potential FusionNeoAntigen Information of TET1-TMEM222 in HLA II

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
TET1-TMEM222_70411693_27660449.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).
Fusion geneHchrHbpTgeneTchrTbpHLA IIFusionNeoAntigen peptideNeoantigen start (at BP 13)Neoantigen end (at BP 13)
TET1-TMEM222chr1070411693chr1276604494576DRB1-0101ENRYWKLDPAQVYAS1126
TET1-TMEM222chr1070411693chr1276604494576DRB1-0101MENRYWKLDPAQVYA1025
TET1-TMEM222chr1070411693chr1276604494576DRB1-0101IMENRYWKLDPAQVY924
TET1-TMEM222chr1070411693chr1276604494576DRB1-0103ENRYWKLDPAQVYAS1126
TET1-TMEM222chr1070411693chr1276604494576DRB1-0103MENRYWKLDPAQVYA1025
TET1-TMEM222chr1070411693chr1276604494576DRB1-0105ENRYWKLDPAQVYAS1126
TET1-TMEM222chr1070411693chr1276604494576DRB1-0105MENRYWKLDPAQVYA1025
TET1-TMEM222chr1070411693chr1276604494576DRB1-0105IMENRYWKLDPAQVY924
TET1-TMEM222chr1070411693chr1276604494576DRB1-0107ENRYWKLDPAQVYAS1126
TET1-TMEM222chr1070411693chr1276604494576DRB1-0107MENRYWKLDPAQVYA1025
TET1-TMEM222chr1070411693chr1276604494576DRB1-0107IMENRYWKLDPAQVY924
TET1-TMEM222chr1070411693chr1276604494576DRB1-0109ENRYWKLDPAQVYAS1126
TET1-TMEM222chr1070411693chr1276604494576DRB1-0109MENRYWKLDPAQVYA1025
TET1-TMEM222chr1070411693chr1276604494576DRB1-0109IMENRYWKLDPAQVY924
TET1-TMEM222chr1070411693chr1276604494576DRB1-0111ENRYWKLDPAQVYAS1126
TET1-TMEM222chr1070411693chr1276604494576DRB1-0111MENRYWKLDPAQVYA1025
TET1-TMEM222chr1070411693chr1276604494576DRB1-0111IMENRYWKLDPAQVY924
TET1-TMEM222chr1070411693chr1276604494576DRB1-0113ENRYWKLDPAQVYAS1126
TET1-TMEM222chr1070411693chr1276604494576DRB1-0113MENRYWKLDPAQVYA1025
TET1-TMEM222chr1070411693chr1276604494576DRB1-0113IMENRYWKLDPAQVY924
TET1-TMEM222chr1070411693chr1276604494576DRB1-0115ENRYWKLDPAQVYAS1126
TET1-TMEM222chr1070411693chr1276604494576DRB1-0115MENRYWKLDPAQVYA1025
TET1-TMEM222chr1070411693chr1276604494576DRB1-0117ENRYWKLDPAQVYAS1126
TET1-TMEM222chr1070411693chr1276604494576DRB1-0117MENRYWKLDPAQVYA1025
TET1-TMEM222chr1070411693chr1276604494576DRB1-0117IMENRYWKLDPAQVY924
TET1-TMEM222chr1070411693chr1276604494576DRB1-0119ENRYWKLDPAQVYAS1126
TET1-TMEM222chr1070411693chr1276604494576DRB1-0119MENRYWKLDPAQVYA1025
TET1-TMEM222chr1070411693chr1276604494576DRB1-0119IMENRYWKLDPAQVY924
TET1-TMEM222chr1070411693chr1276604494576DRB1-0121ENRYWKLDPAQVYAS1126
TET1-TMEM222chr1070411693chr1276604494576DRB1-0121MENRYWKLDPAQVYA1025
TET1-TMEM222chr1070411693chr1276604494576DRB1-0121IMENRYWKLDPAQVY924
TET1-TMEM222chr1070411693chr1276604494576DRB1-0125ENRYWKLDPAQVYAS1126
TET1-TMEM222chr1070411693chr1276604494576DRB1-0125MENRYWKLDPAQVYA1025
TET1-TMEM222chr1070411693chr1276604494576DRB1-0125IMENRYWKLDPAQVY924
TET1-TMEM222chr1070411693chr1276604494576DRB1-0127ENRYWKLDPAQVYAS1126
TET1-TMEM222chr1070411693chr1276604494576DRB1-0127MENRYWKLDPAQVYA1025
TET1-TMEM222chr1070411693chr1276604494576DRB1-0127IMENRYWKLDPAQVY924
TET1-TMEM222chr1070411693chr1276604494576DRB1-0129ENRYWKLDPAQVYAS1126
TET1-TMEM222chr1070411693chr1276604494576DRB1-0129MENRYWKLDPAQVYA1025
TET1-TMEM222chr1070411693chr1276604494576DRB1-0129IMENRYWKLDPAQVY924
TET1-TMEM222chr1070411693chr1276604494576DRB1-0131ENRYWKLDPAQVYAS1126
TET1-TMEM222chr1070411693chr1276604494576DRB1-0131MENRYWKLDPAQVYA1025
TET1-TMEM222chr1070411693chr1276604494576DRB1-0131IMENRYWKLDPAQVY924
TET1-TMEM222chr1070411693chr1276604494576DRB1-0305ENRYWKLDPAQVYAS1126
TET1-TMEM222chr1070411693chr1276604494576DRB1-0305MENRYWKLDPAQVYA1025
TET1-TMEM222chr1070411693chr1276604494576DRB1-0338ENRYWKLDPAQVYAS1126
TET1-TMEM222chr1070411693chr1276604494576DRB1-0338MENRYWKLDPAQVYA1025
TET1-TMEM222chr1070411693chr1276604494576DRB1-0338IMENRYWKLDPAQVY924
TET1-TMEM222chr1070411693chr1276604494576DRB1-0340ENRYWKLDPAQVYAS1126
TET1-TMEM222chr1070411693chr1276604494576DRB1-0340MENRYWKLDPAQVYA1025
TET1-TMEM222chr1070411693chr1276604494576DRB1-0704ENRYWKLDPAQVYAS1126
TET1-TMEM222chr1070411693chr1276604494576DRB1-0807ENRYWKLDPAQVYAS1126
TET1-TMEM222chr1070411693chr1276604494576DRB1-0819ENRYWKLDPAQVYAS1126
TET1-TMEM222chr1070411693chr1276604494576DRB1-0819MENRYWKLDPAQVYA1025
TET1-TMEM222chr1070411693chr1276604494576DRB1-0825ENRYWKLDPAQVYAS1126
TET1-TMEM222chr1070411693chr1276604494576DRB1-0825MENRYWKLDPAQVYA1025
TET1-TMEM222chr1070411693chr1276604494576DRB1-0832ENRYWKLDPAQVYAS1126
TET1-TMEM222chr1070411693chr1276604494576DRB1-0834ENRYWKLDPAQVYAS1126
TET1-TMEM222chr1070411693chr1276604494576DRB1-0834MENRYWKLDPAQVYA1025
TET1-TMEM222chr1070411693chr1276604494576DRB1-1001ENRYWKLDPAQVYAS1126
TET1-TMEM222chr1070411693chr1276604494576DRB1-1001MENRYWKLDPAQVYA1025
TET1-TMEM222chr1070411693chr1276604494576DRB1-1001IMENRYWKLDPAQVY924
TET1-TMEM222chr1070411693chr1276604494576DRB1-1003ENRYWKLDPAQVYAS1126
TET1-TMEM222chr1070411693chr1276604494576DRB1-1003MENRYWKLDPAQVYA1025
TET1-TMEM222chr1070411693chr1276604494576DRB1-1003IMENRYWKLDPAQVY924
TET1-TMEM222chr1070411693chr1276604494576DRB1-1201SVAAVREIMENRYWK217
TET1-TMEM222chr1070411693chr1276604494576DRB1-1205SVAAVREIMENRYWK217
TET1-TMEM222chr1070411693chr1276604494576DRB1-1206SVAAVREIMENRYWK217
TET1-TMEM222chr1070411693chr1276604494576DRB1-1207SVAAVREIMENRYWK217
TET1-TMEM222chr1070411693chr1276604494576DRB1-1210SVAAVREIMENRYWK217
TET1-TMEM222chr1070411693chr1276604494576DRB1-1211SVAAVREIMENRYWK217
TET1-TMEM222chr1070411693chr1276604494576DRB1-1212SVAAVREIMENRYWK217
TET1-TMEM222chr1070411693chr1276604494576DRB1-1214SVAAVREIMENRYWK217
TET1-TMEM222chr1070411693chr1276604494576DRB1-1216ENRYWKLDPAQVYAS1126
TET1-TMEM222chr1070411693chr1276604494576DRB1-1216MENRYWKLDPAQVYA1025
TET1-TMEM222chr1070411693chr1276604494576DRB1-1217SVAAVREIMENRYWK217
TET1-TMEM222chr1070411693chr1276604494576DRB1-1222ENRYWKLDPAQVYAS1126
TET1-TMEM222chr1070411693chr1276604494576DRB1-1222MENRYWKLDPAQVYA1025
TET1-TMEM222chr1070411693chr1276604494576DRB1-1222IMENRYWKLDPAQVY924
TET1-TMEM222chr1070411693chr1276604494576DRB1-1419ENRYWKLDPAQVYAS1126
TET1-TMEM222chr1070411693chr1276604494576DRB1-1446ENRYWKLDPAQVYAS1126
TET1-TMEM222chr1070411693chr1276604494576DRB1-1446MENRYWKLDPAQVYA1025
TET1-TMEM222chr1070411693chr1276604494576DRB1-1447ENRYWKLDPAQVYAS1126
TET1-TMEM222chr1070411693chr1276604494576DRB1-1448ENRYWKLDPAQVYAS1126
TET1-TMEM222chr1070411693chr1276604494576DRB1-1448MENRYWKLDPAQVYA1025
TET1-TMEM222chr1070411693chr1276604494576DRB1-1449ENRYWKLDPAQVYAS1126
TET1-TMEM222chr1070411693chr1276604494576DRB1-1449MENRYWKLDPAQVYA1025
TET1-TMEM222chr1070411693chr1276604494576DRB1-1451ENRYWKLDPAQVYAS1126
TET1-TMEM222chr1070411693chr1276604494576DRB1-1493ENRYWKLDPAQVYAS1126
TET1-TMEM222chr1070411693chr1276604494576DRB1-1493MENRYWKLDPAQVYA1025
TET1-TMEM222chr1070411693chr1276604494576DRB1-1601ENRYWKLDPAQVYAS1126
TET1-TMEM222chr1070411693chr1276604494576DRB1-1603ENRYWKLDPAQVYAS1126
TET1-TMEM222chr1070411693chr1276604494576DRB1-1604ENRYWKLDPAQVYAS1126
TET1-TMEM222chr1070411693chr1276604494576DRB1-1608ENRYWKLDPAQVYAS1126
TET1-TMEM222chr1070411693chr1276604494576DRB1-1609ENRYWKLDPAQVYAS1126
TET1-TMEM222chr1070411693chr1276604494576DRB1-1610ENRYWKLDPAQVYAS1126
TET1-TMEM222chr1070411693chr1276604494576DRB3-0101ENRYWKLDPAQVYAS1126
TET1-TMEM222chr1070411693chr1276604494576DRB3-0101MENRYWKLDPAQVYA1025
TET1-TMEM222chr1070411693chr1276604494576DRB3-0101IMENRYWKLDPAQVY924
TET1-TMEM222chr1070411693chr1276604494576DRB3-0104ENRYWKLDPAQVYAS1126
TET1-TMEM222chr1070411693chr1276604494576DRB3-0104MENRYWKLDPAQVYA1025
TET1-TMEM222chr1070411693chr1276604494576DRB3-0104IMENRYWKLDPAQVY924
TET1-TMEM222chr1070411693chr1276604494576DRB3-0105ENRYWKLDPAQVYAS1126
TET1-TMEM222chr1070411693chr1276604494576DRB3-0105MENRYWKLDPAQVYA1025
TET1-TMEM222chr1070411693chr1276604494576DRB3-0105IMENRYWKLDPAQVY924
TET1-TMEM222chr1070411693chr1276604494576DRB3-0108ENRYWKLDPAQVYAS1126
TET1-TMEM222chr1070411693chr1276604494576DRB3-0108MENRYWKLDPAQVYA1025
TET1-TMEM222chr1070411693chr1276604494576DRB3-0108IMENRYWKLDPAQVY924
TET1-TMEM222chr1070411693chr1276604494576DRB3-0109ENRYWKLDPAQVYAS1126
TET1-TMEM222chr1070411693chr1276604494576DRB3-0109MENRYWKLDPAQVYA1025
TET1-TMEM222chr1070411693chr1276604494576DRB3-0109IMENRYWKLDPAQVY924
TET1-TMEM222chr1070411693chr1276604494576DRB3-0111ENRYWKLDPAQVYAS1126
TET1-TMEM222chr1070411693chr1276604494576DRB3-0111MENRYWKLDPAQVYA1025
TET1-TMEM222chr1070411693chr1276604494576DRB3-0111IMENRYWKLDPAQVY924
TET1-TMEM222chr1070411693chr1276604494576DRB3-0112ENRYWKLDPAQVYAS1126
TET1-TMEM222chr1070411693chr1276604494576DRB3-0112MENRYWKLDPAQVYA1025
TET1-TMEM222chr1070411693chr1276604494576DRB3-0112IMENRYWKLDPAQVY924
TET1-TMEM222chr1070411693chr1276604494576DRB3-0113ENRYWKLDPAQVYAS1126
TET1-TMEM222chr1070411693chr1276604494576DRB3-0113MENRYWKLDPAQVYA1025
TET1-TMEM222chr1070411693chr1276604494576DRB3-0113IMENRYWKLDPAQVY924
TET1-TMEM222chr1070411693chr1276604494576DRB3-0114ENRYWKLDPAQVYAS1126
TET1-TMEM222chr1070411693chr1276604494576DRB3-0114MENRYWKLDPAQVYA1025
TET1-TMEM222chr1070411693chr1276604494576DRB3-0114IMENRYWKLDPAQVY924
TET1-TMEM222chr1070411693chr1276604494576DRB3-0205ENRYWKLDPAQVYAS1126
TET1-TMEM222chr1070411693chr1276604494576DRB3-0209ENRYWKLDPAQVYAS1126
TET1-TMEM222chr1070411693chr1276604494576DRB3-0209MENRYWKLDPAQVYA1025
TET1-TMEM222chr1070411693chr1276604494576DRB3-0213ENRYWKLDPAQVYAS1126
TET1-TMEM222chr1070411693chr1276604494576DRB3-0213MENRYWKLDPAQVYA1025
TET1-TMEM222chr1070411693chr1276604494576DRB3-0216ENRYWKLDPAQVYAS1126
TET1-TMEM222chr1070411693chr1276604494576DRB3-0216MENRYWKLDPAQVYA1025
TET1-TMEM222chr1070411693chr1276604494576DRB3-0219ENRYWKLDPAQVYAS1126
TET1-TMEM222chr1070411693chr1276604494576DRB3-0219MENRYWKLDPAQVYA1025
TET1-TMEM222chr1070411693chr1276604494576DRB3-0221ENRYWKLDPAQVYAS1126
TET1-TMEM222chr1070411693chr1276604494576DRB3-0221MENRYWKLDPAQVYA1025
TET1-TMEM222chr1070411693chr1276604494576DRB3-0222ENRYWKLDPAQVYAS1126
TET1-TMEM222chr1070411693chr1276604494576DRB3-0222MENRYWKLDPAQVYA1025
TET1-TMEM222chr1070411693chr1276604494576DRB3-0303ENRYWKLDPAQVYAS1126
TET1-TMEM222chr1070411693chr1276604494576DRB3-0303MENRYWKLDPAQVYA1025

Top

Fusion breakpoint peptide structures of TET1-TMEM222

check button3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.
File nameBPseqHgeneTgeneHchrHbpTchrTbpAAlen
10229VREIMENRYWKLDPTET1TMEM222chr1070411693chr1276604494576

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of TET1-TMEM222

check buttonVirtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.
HLA allelePDB IDFile nameBPseqDocking scoreGlide score
HLA-B14:023BVN10229VREIMENRYWKLDP-6.46878-6.66328
HLA-B14:023BVN10229VREIMENRYWKLDP-4.33704-5.09154
HLA-B52:013W3910229VREIMENRYWKLDP-6.45088-7.20538
HLA-B52:013W3910229VREIMENRYWKLDP-6.08714-6.28164
HLA-A11:014UQ210229VREIMENRYWKLDP-7.67344-8.42794
HLA-A24:025HGA10229VREIMENRYWKLDP-7.49907-7.69357
HLA-A24:025HGA10229VREIMENRYWKLDP-4.36357-5.11807
HLA-B27:056PYJ10229VREIMENRYWKLDP-8.53231-9.28681
HLA-B44:053DX810229VREIMENRYWKLDP-5.69992-5.89442
HLA-B44:053DX810229VREIMENRYWKLDP-3.58931-4.34381
HLA-B35:011A1N10229VREIMENRYWKLDP-7.72945-7.92395
HLA-B35:011A1N10229VREIMENRYWKLDP-4.44046-5.19496
HLA-A02:016TDR10229VREIMENRYWKLDP-7.78181-7.97631

Top

Vaccine Design for the FusionNeoAntigens of TET1-TMEM222

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptide sequenceFusionNeoAntigen RNA sequence
TET1-TMEM222chr1070411693chr1276604491018MENRYWKLGGAGAATAGGTACTGGAAGTTGGA
TET1-TMEM222chr1070411693chr1276604491221NRYWKLDPATAGGTACTGGAAGTTGGACCCTGCTCA
TET1-TMEM222chr1070411693chr127660449414AAVREIMENRTGCTGTCAGGGAAATCATGGAGAATAGGTA
TET1-TMEM222chr1070411693chr127660449514AVREIMENRTGTCAGGGAAATCATGGAGAATAGGTA
TET1-TMEM222chr1070411693chr127660449515AVREIMENRYTGTCAGGGAAATCATGGAGAATAGGTACTG
TET1-TMEM222chr1070411693chr127660449516AVREIMENRYWTGTCAGGGAAATCATGGAGAATAGGTACTGGAA
TET1-TMEM222chr1070411693chr127660449616VREIMENRYWCAGGGAAATCATGGAGAATAGGTACTGGAA
TET1-TMEM222chr1070411693chr127660449715REIMENRYGGAAATCATGGAGAATAGGTACTG
TET1-TMEM222chr1070411693chr127660449716REIMENRYWGGAAATCATGGAGAATAGGTACTGGAA
TET1-TMEM222chr1070411693chr127660449918IMENRYWKLCATGGAGAATAGGTACTGGAAGTTGGA

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptideFusionNEoAntigen RNA sequence
TET1-TMEM222chr1070411693chr1276604491025MENRYWKLDPAQVYAGGAGAATAGGTACTGGAAGTTGGACCCTGCTCAGGTCTATGCTAG
TET1-TMEM222chr1070411693chr1276604491126ENRYWKLDPAQVYASGAATAGGTACTGGAAGTTGGACCCTGCTCAGGTCTATGCTAGCGG
TET1-TMEM222chr1070411693chr127660449217SVAAVREIMENRYWKTGTTGCTGCTGTCAGGGAAATCATGGAGAATAGGTACTGGAAGTT
TET1-TMEM222chr1070411693chr127660449924IMENRYWKLDPAQVYCATGGAGAATAGGTACTGGAAGTTGGACCCTGCTCAGGTCTATGC

Top

Information of the samples that have these potential fusion neoantigens of TET1-TMEM222

check button These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.
Cancer typeFusion geneHchrHbpHenstTchrTbpTenstSample
SARCTET1-TMEM222chr1070411693ENST00000373644chr127660449ENST00000374076TCGA-IF-A4AK-01A

Top

Potential target of CAR-T therapy development for TET1-TMEM222

check button Predicted 3D structure. We used RoseTTAFold.

check buttonRetention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features


* Minus value of BPloci means that the break point is located before the CDS.
- In-frame and retained 'Transmembrane'.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note
TgeneTMEM222chr10:70411693chr1:27660449ENST0000037407626165_1850209.0TransmembraneHelical
TgeneTMEM222chr10:70411693chr1:27660449ENST0000037407626187_2070209.0TransmembraneHelical

check button Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.
HgeneHchrHbpHenstTgeneTchrTbpTenstDeepLoc result

Top

Related Drugs to TET1-TMEM222

check button Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDrugSourcePMID

Top

Related Diseases to TET1-TMEM222

check button Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDiseaseSourcePMID

check button Diseases associated with fusion partners.
(DisGeNet 4.0)
PartnerGeneDisease IDDisease name# pubmedsSource
HgeneTET1C0033975Psychotic Disorders1PSYGENET
HgeneTET1C0036341Schizophrenia1PSYGENET
HgeneTET1C0349204Nonorganic psychosis1PSYGENET
HgeneTET1C1510586Autism Spectrum Disorders1CTD_human